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Currently, the world turns toward using charged particle radiotherapy, as protons and 
heavy ions share an advantage to achieve a more conformal physical dose distribution 
to the tumour than the conventional methods by photons. There is increased demand 
in a scientific community of moving from a relative biological effectiveness, RBE, of 
1.1 for protons and to step aside from this generic-value through consistency by a 
linear energy transfer, LET, and make validation of one of RBE models to investigate 
how LET calculation can be used in the treatment planning process. The LET and 
RBE will investigated for a water-phantom and brain tumor patient case in this 
project. 
The scientific community notably distinguished of Bragg-peak phenomenon which 
have higher LET value and simultaneously helping to avoid the co-irradiation of 
normal tissue compared to conventual radiotherapy features of low-LET value. The 
charged particles therapy of higher of LET value concentrates to the tumour that 
resistant of conventual radiotherapy and to tumour nearby location to critical organs, 
it used this type of treatment clinically limited of certain tumour kinds, for instance, 
skull base tumours, pediatric tumours, due to there is difficulty predict precisely of 
side effects on long-term like second malignant or hazard of late normal tissue harm. 
Protons have higher biological effect compared to photons, which is clinically 
representatives by a generic relative biological effectiveness (RBE), equal 1.1.  
The biological effect or namely, RBE, mainly relies on the manner of the density of 
ionization actions along the track of radiation namely the absorbed dose distribution 
and LET, where studies showed at the distal end of the proton beam the RBE value is 
rising with the rise in value of LET. In proton therapy, two methods utilized for 
delivering the treatment through passive scattering or pencil beam scanning, the latter 
is the most current state and widely used which can lead to higher average LET, with 
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perhaps additional biological effects due to variations in how the protons are 
modulated compared with passive scattering. In the original treatment plan when 
computing the relative biological effectiveness (RBE) does not bear in mind the LET. 
The accuracy of delivery prescription dose in trade treatment planning systems (TPS) 
renounce in order to capitalize on the TPS calculation in a reasonable time-scale. At 
present, Monte Carlo (MC) code simulations are the gold standard in dose 
calculation, but its use in clinical work is still limited due to the long computational 
time needed. The FLUKA MC tool has been used for recalculation of dose, LET and 
RBE distributions in this work. A prototype LET estimator integrated into FLUKA 
was also used.  
The aim of this work is to recalculate the biological dose of TPS by FLUKA MC and 
calculate the corresponding LET using FLUKA and Eclipse utilizing a script called 
Micro-Calculation especially for Eclipse in order to LET calculation as well as inspect 
the RBE-McNamara model values at LET for both techniques, and verify this.  
The results showed relatively good agreement for the comparison of biological dose 
between FLUKA MC and Eclipse (TPS), through utilized the Micro-Calculation 
script in Eclipse software to calculate the LETd value gave higher outcomes than 
FLUKA MC calculated in some of the studied organs. The RBE-MCN values was for 
the good of calculated of FLUKA MC than the Eclipse Micro-Calculation for all 
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Cancer is a group of diseases characterized by cells beginning to divide without stopping and 
spread of abnormal cells into surrounding tissues. There are over 100 types of cancer (National 
Cancer Institute, 2015). Many people around the world are infected with cancer, often leading 
to premature death when diagnosis and treatment are not done right. Cancer is the second 
leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. 
Globally, about 1 in 6 deaths is due to cancer (World Health Organization, 2018,September ). 
There are many ways to treat cancer. Treatment can include chemotherapy, hormone 
therapy, surgery, immunotherapy and radiotherapy. These treatments can be used separately 
or in combination. The type of treatment will depend on the type of cancer (Institute, 
2019,July ). Radiotherapy plays a major role in cancer care, a correct and early diagnosis 
gives a better chance of survival as this can determine the extent and location of cancer, 
which helps specialists determine cancer type and appropriate treatment method (Institute, 
2019,July ). 
There are several methods to help disclose cancer that can assist doctors in diagnosis, for 
instance, laboratory tests made by blood or urine tests, biopsy as the doctor gathers samples 
of cells for testing or by imaging tests, allow to generate pictures of regions inside the patient 
bode, the pictures can be made in a few different ways like magnetic resonance imaging 
(MRI), computed tomography (CT) scan, positron emission tomography (Yamoah & 
Johnstone) scan, X-ray and ultrasound. Under of the computerized development that has 
taken place in recent years, revolutionary progress has been made in the treatment of 
radiation oncology, these developments have helped to make radiography more accurate in 
the three spatial and fourth (temporal) dimensions, computerized planning systems have 
also helped to makes 3D measurements more ease and accuracy.  
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One of the methods in radiotherapy is external radiation therapy, the patient irradiated from 
the outside by photon or heavy particles. The aim of radiotherapy is to eliminate cancer cells 
by delivery of enough doses to the target and avoid the surrounding healthy tissue at the 
same time. The heavy particles usually utilize to irradiate due to their characteristic as know 
Bragg peak has virtually no exit dose. The successful treatment depends on many factors, 
one of the factors determining the success of radiation therapy is determining the 
appropriate and sufficient dose for the target, diagnostic medical imaging is carried out 
through one of the methods mentioned above previously and consequently determines the 
volume of the target whereupon the dose calculation is based (Khan & Gibbons, 2014). 
 
   
1.1 Radiotherapy  
Radiotherapy is a treatment utilized ionizing radiation aiming to deliver an adequate and 
uniform dose to kill cancer or malignant cells and to achieve tumor control, while meanwhile, 
as far as possible, avoid normal organs and healthy tissue.   
Radiotherapy can be delivered both internally or as external radiotherapy: In internal 
radiotherapy, also called brachytherapy, radioactive sources are implanted inside the patient. 
In external radiotherapy radiation from a source outside the patient is used. This can be from 
a radioactive source or from equipment such as a linear accelerator (LINAC). The radiation 
can be photons (x-rays), electrons, and heavy charged particles such as protons or carbon 
ions (Use, 2008). 
There are various types of external radiotherapy, all share the aim of delivery of the required 
rays to the tumor while avoiding the normal tissues around it. Each type depends on a 
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method for calculating and analyze images of the tumor to account the dose and the accurate 
way of treatment, examples of these types:  
I. 3D Conformal Radiotherapy (CRT), this implies that beams are uniquely shaped to fit 
the infected region. In 3D CRT the radiation beams used in treatments are of uniform 
intensity across the field (Webb, 1997). 
II. Intensity-Modulated Radiotherapy (IMRT) allows for better tumor inclusion and 
sparing normal tissue than 3D CRT, as in IMRT the intensity beam profile is modified 
and delivered with nonuniform fluence using dynamic multileaf collimators (MLC), 
which can shape the treatment area with high precision and avoid the vital organ of the 
radiation dose (Khan & Gibbons, 2014).  
III. Volumetric-Modulated Arc Radiotherapy, VMAT, is a more modern form of IMRT, in 
this radiation therapy technique the LINAC machine rotates continuously during 
delivery of the radiation dose and changes the intensity of the radiation beam according 
the treatment area. This makes VMAT progressively precise and abbreviate the 
treatment time (Teoh, Clark, Wood, Whitaker, & Nisbet, 2011). 
IV. Image-Guide Radiotherapy, IGRT, is the use of imaging during radiation therapy to 
improve the precision and accuracy of treatment delivery. Radiation therapy machines, 
LINAC, merge with imaging technologies like CT to image the tumor before and during 
the treatment (Jaffray, 2012). 
V. Four-Dimensional Radiotherapy, 4D Radiotherapy, previous methods of radiotherapy 
may not always be safe for normal tissues that are adjacent, especially tumor sites in the 
thorax and abdomen due to respiration process. This leads to difference between the 
planned and presented doses and the inaccuracy of the hit the target. By monitoring 
motion, time is added as a fourth dimension to track the motion of patient (Gui, Feng, 
Yi, Dhople, & Yu, 2010). 
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VI. Stereotactic Radiotherapy, SRT, is good choice for small tumor or cancer due to the 
method is of focused many beams towards a tumor at different angles. There are two 
types of stereotactic radiation: 
1- stereotactic Radiosurgery, (SRS), for brain. 
 2- stereotactic Body Radiotherapy, (SBRT), for all body (Song, Park, Griffin, & Levitt, 
2011). 
1.2 Proton Therapy  
Robert R. Wilson is the physicist that in 1946 suggested using protons in radiotherapy. 
Wilson showed the advantages of protons compared with conventional photon therapy. He 
outlined the idea for treating tumors utilizing the finite range and the Bragg peak of proton 
beams (Bragg & Kleeman, 1905; Wilson, 1946). 
The concept of proton therapy was not immediately implemented at Wilsonʼs home 
institution at Harvard University, however, after a couple of years, Lawrence Berkeley 
Laboratory (LBL) in California applied the concept and treated the first patient in 1954 
(Lawrence, 1957). Other ions such as helium and carbon ions were also applied in therapy, 
and the term particle therapy is used to describe radiotherapy with accelerated ions. 
After the first patient treated by proton therapy at LBL, in 1955 Gustav Werner Institute in 
Sweden started medical use of protons and arrangement of animalʼs tests were performed to 
study the biological effect of proton radiation and in 1957 the first patient was treated using 
a 185-MeV cyclotron (Chaturvedi et al., 2007; Hawkins, Draper, & Kingston, 1987; Rydberg, 
1996). The merit of proton radiation therapy compared with conventional photon radiation 
therapy made the world more interested in using proton therapy in cancer treatment. 
Today, 103 proton therapy centers are clinically active worldwide, and many more are under 
planning, including two centers in Norway. Over 180 000 patients worldwide has been 
17 
 




Figure 1. Comparison of relative depth dose distribution of protons in a water phantom versus 
photons and electrons, the blue dashed line representing the energy distribution of the proton beam 
as a function of depth in a target. the Black dotted indicate for photon distribution as a function of 
depth. Gray dotted/dashed line plots the electron distribution as a function of depth. Red-line 
outlines the combination of multiple proton beams, forming a spread-out Bragg peak (SOBP) for 
protons (Yamoah & Johnstone, 2016). 
 





The finite range of a proton beam is the most distinguished difference between photon and 
proton beams. In addition, as protons penetration through the matter, the velocity of the 
protons is reduced due to the interaction with the matter and this causes the dose deposition 
of protons to increase with depth until the energy of the protons is completely exhausted and 
they stop. This leads to a maximum dose deposition at a certain depth in matter with a peak 
and then a sharp drop off in dose distal to the peak. The peak is called the “Bragg peak” 
(Tayama et al., 2002). This is unlike photons and electrons where the build-up deposition 
dose region at the initial of their path and dose deposition decreasing after the build-up 
region as distance increases in the matter (Mohan, Mahajan, & Minsky, 2013; Yamoah & 
Johnstone, 2016). 
Protons and photons have different biological effectiveness, concept of the relative biological 
effectiveness (RBE) was introduced to represent the different biological effects, defined as 
the ratio between the dose from 60Co g-rays and dose from another radiation that produces 
the same biological end-point. In clinical proton therapy, a generic RBE of 1.1 is currently 
used. However, according to experimental data, the RBE of protons is not constant, and in 
vitro irradiation experiments has shown that the RBE depends on many factors like physical 
dose, linear energy transfer (LET), and (𝛼⁄𝛽)-ratio of the Linear Quadratic (LQ) model 
(Harald Paganetti et al., 2002). The LET describes the energy lost/deposition per unit path 
length along with the particle track and is handily expressed in units of keV/μm. The LET 
decrease as the proton energy increases as Figure 2 shows and therefore depends on the 
particle energy (Mori, Sakae, Takada, & Takei, 2020). 
1.3 Project Objectives/Motivation  
There is an increasing consensus in the scientific community that using an RBE of 1.1 is 
insufficient and that the variations in RBE with LET should be taken into account in proton 
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therapy. Until recently, LET has only been available through the use of general-purpose 
Monte Carlo codes. However, prototype LET estimators are now becoming available in 
commercial treatment planning systems (TPS). 
The biological effects in radiotherapy need careful evaluation to achieve the treatment with 
fewer disadvantages, and regardless of the increasing use of proton therapy there stay two 
critical uncertainties related to proton therapy: The insufficient information of relative 
biological effectiveness, RBE, at various doses and in various tissues and accuracy of Bragg 
peak position (B. Jones, 2015). For proton therapy treatment, the RBE-weighted or so-called 
biological dose considered as the key for determining dose prescription in proton therapy 
(Beyzadeoglu, Ozyigit, & Selek, 2012). The relative biological effect computation is difficult 
since it depends on linear energy transfer and the type of tissue response must be known 
with high precision (Harald Paganetti, 2003).  
Since of the significant importance of performing the linear energy transfer and related 
relative biological efficacy with dose in proton therapy treatment, this study aims to compare 
proton dose and LET calculations from the Eclipse treatment planning system (TPS) and 
FLUKA Monte Carlo (MC). These LET estimators has been used separately before but a 
comparison of the two has not been done. On one hand, the MC approach is considered the 
most reliable, but is difficult to apply in a clinical setting. It is therefore of high importance to 
investigate if there is agreement or differences between the two methods. 
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2. Physics of Particle Therapy 
In medical physics, the charged particles (protons and light ions) in radiation therapy is one 
of the most successful cases for treating cancer without external surgical intervention. The 
biological properties of ionizing radiation in addition to the physical features in terms of 
accuracy make charged particles a favorable choice  in clinical terms (G Battistoni, Mattei, & 
Muraro, 2016). The principle of particle therapy is based on the interaction of charged 
particles with matter and they deposit their energy to a specified target through ionizing the 
target atoms (Lomax, 2009). The basic interaction of protons with matter will be shown in 
this chapter. 
2.1 Interactions 
Materials consists of atoms and it constitutes a mixture of electrons and nuclei. Protons, and 
other charged particles interact with the electrons and nuclei and lose their energy during the 
interaction in different mechanisms: inelastic interaction with atomic electrons, elastic 
interactions with atomic nucleons, nuclear interaction with nucleus and Bremsstrahlung 
(Tsuboi, 2020), the latter case effect is negligible at therapy proton (Newhauser & Zhang, 




Figure 3. Illustration of three proton interaction processes. A) the proton energy loss based on 
inelastic Coulomb interaction. B) The proton deviation from trajectory due to repulsive Coulomb 
elastic scatter with the nucleus. C) The proton deviation from trajectory due to repulsive Coulomb 
elastic scatter with the nucleus, resulting in formation of secondary particles and removal of the 
primary proton by nuclear interaction (Newhauser & Zhang, 2015). 
2.1.1 Inelastic interactions with atomic electrons 
Interaction the protons and atomic electrons by Coulomb interaction represents the basic 
process, causing atomic exciting or ionizing with negligible deflection of the primary proton 
due to proton mass being 1843 times greater than the electron mass (Newhauser & Zhang, 
2015; Park & Kang, 2011). 
The energy transferred from proton to electron at each interaction is considered a tiny amount 
of energy to release the electron from an atom, i.e. ionization, the recoil electrons that have 
low kinetic energy precipitation their energy locally (Takei, 2020). There are a few electrons 
that get enough energy to ionize nearby atoms by a process called second ionization, these 
electrons are known as d-rays (Takei, 2020). 
The protons lose their kinetic energy as a result of interactions during the movement time in 
the medium. The medium has the capability to stop protons and this capability known as 
linear stopping power and denotes by S, and it described the energy loss of charged particle, 







The stopping power has unit   MeV m/ .  
S consisting of three parts,  S!" , S#$% and S&'(: 
 











S!" is the electronic stopping power in respect of inelastic interactions with atomic electrons, 
S#$% is the radiative stopping power due to Bremsstrahlung, S&'( is the nuclear stopping 
power because of elastic Coulomb interaction with the target nuclei. For non-elastic nuclear 
interaction mechanisms are not usually described by a stopping power (Thomas, 2012). 
The electronic stopping power is the dominant process and for nuclear stopping power 
becomes important for heavier particles than the proton, the radiative stopping power 
contribution is lower than elastic Coulomb interaction with the target nuclei so can be 




  (Elia, 2019). 
Bethe (Bethe, 1930) and Block (Bloch, 1933) developed the theory of the proton energy loss 
which considers the electronic stopping power is the dominated process (Elia, 2019), the 
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Table 1. Parameters of Bethe-Block equation 
Parameters description                 Parameters description                 
N$  Avogadroʼs number.                     
r! Classical electron radius.                                         
m! Atomic mass.                            
c Speed of light in vacuum.                         
r Density of the absorbing   material. 
Z Atomic number of absorbing materials. 
A Atomic mass of absorbing material.   
                     
z Charge of the incident particle. 
g Lorentz-factor 
                       
v Speed of incident Particle 
 
W,$*	Maximum energy transfer in a 
single collision. 
 
I Mean excitation potential. 
 
C Shell correction. 
 
d Density correction. 
 
b = v c⁄  Relativistic velocity. 
 
 
The Bethe-Block equation describes how much the charged particle that loses energy, dE, 
along the done path, dx	, in the medium. The formula shows how the particle projectile 
characteristics affect the energy loss which it is proportional to square of the charge particle 
and to the inverse square of velocity (Newhauser & Zhang, 2015). 
2.1.2 Coulomb scattering 
From the classical approach, a proton undergoes a repulsive force whilst proton passed close 
to the atomic nucleus makes the proton deflect from its original trajectory, this process is 
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called Coulomb interaction or proton-nucleus elastic scattering and it is the main mechanism 
interaction with the atomic nucleus (Newhauser & Zhang, 2015; Tsuboi, 2020). It is 
necessary to take into account this type of mechanism in dose calculation of dose distribution 
whether for patient or phantom with treatment planning systems (Newhauser & Zhang, 
2015). 
In clinical particle, Coulombe scattering plays a part in loss energy which is within 0.1% of 
overall energy loss (Elia, 2019). This procedure significantly recurrent elastic scattering on 
nuclei (Multiple Coulomb Scattering, MCS) leads to the lateral penumbra of proton beams 
as a function of depth, this can cause the lateral beam spread (Eric Shinohara MD, 2016, 
November 30; Harald Paganetti, 2018). 
2.1.3 Nuclear interactions 
The collision between the proton and nucleus can be elastic or non-elastic scattering, in the 
elastic scattering process the primary proton scattering with a large angle and the kinetic 
energy is conserved, the target nucleus only recoils (Breuer & Smit, 2013). In non-elastic 
scattering, the protons impart their energy to the target nuclei, and the target breaks apart to 
recoil nuclei and secondary particles, like secondary protons, neutrons, a particles, and g rays 
(Tsuboi, 2020). 
In the point of interaction, the recoil nuclei and the fragment are absorbed and the secondary 
protons are scattered large distance from the point of interaction, it contributes to a low 
dose, halo influence, which must take into account for dose distribution and unwanted 
neutrons production (Hoppe, Phillips, & Roach, 2010). Although the nuclear interaction is 
less frequent than proton-electron interaction and Coulomb interaction (Hoppe et al., 2010; 
Tsuboi, 2020), the probability of this interaction increase with the protonʼs energy and 




2.1 Depth Dose Curves and Dosimetry 
In radiotherapy and radiation protection, a unit was placed that helped measure tissue 
damage caused through ionizing radiation, it is considered the precision of determining the 
absorbed dose key succeed major in radiotherapy treatment where help to avoid the damage 
to healthy tissue in case increase dose about the required limit or failure to control tumor if 
the dose decreases below the required limit. 
2.4.1 Absorbed dose 
The damage to irradiated material(tissue/organ) is measure by the energy that has been 
amount absorbed by it. The mean energy dE imparted and deposited to a material volume dV 










Where ρ the density of material. Absorbed/physical dose, in the SI system uses Gray (Gy) 
measuring unit, where 1 Gy equal to 1 joule per kilogram (Baltas, Sakelliou, & Zamboglou, 
2006).  
2.4.2 Equivalent dose 
Each organ and tissue have a special sensitivity to the type of radiation, which is not included 
in the concept of equivalent dose. The concept of equivalent dose takes into consideration 








Where w- represents the weighting factor for distinction radiation type set out in the Table 
2, and D.,- is the absorbed dose over the tissue. The unit of measure is the Sievert (Sv) 
express as 1sv= J kg-1 (Charles, 2008). 
 
Table 2. Radiation weighting factors as delimited by the International Commission on Radiological 
Protection (ICRP)(Charles, 2008). 
Radiation types Weighting factor, w- 
Protons and charged ions 
Photons 
Electrons and muons 
Alpha particles, fission fragments and 
heavy ions 
Neutrons: 
En < 1MeV 
1MeV ≤ En ≤ 50MeV  











2.4.3 Effective dose 
Each organ and tissue have a special sensitivity to the direction of radiation which is not 
included in the concept of equivalent dose, the International Commission on Radiological 










Where w. represent the tissue weighting factor, Table 3 classify the w. factor(Charles, 
2008). 
 
Table 3. Tissue weighting factors(Charles, 2008). 
Tissue/organ Weighting factor,	w. 
Brain, bone surface, skin, salivary glands. 
Esophagus, bladder, liver, thyroid. 
Gonads. 
Marrow, breast, lung, bone, colon, stomach, remaining 
tissues (Prostate, adrenals, kidneys, extra thoracic region, gallbladder, heart, 
lymphatic nodes, muscle, thymus, pancreas, small intestine, spleen, uterus, 







2.4.4 Isoeffective dose 
The IAEA (International Atomic Energy Agency) and ICRU took addition factors into 
consideration for combined or compared various types of treatment, and insert the 
isoeffective absorbed dose,	D012), concept. isoeffective absorbed dose is the dose the 
conveyed undergoing the reference conditions, for instance (photon, 2Gy/fr, 5fr/week), to 
produce the very effects like the actual treatment D012) = D ×W012). 
D the total delivered dose, W012) weighting factor, which considers all factors (biological 
effects, RBE, LET, dose per fraction, dose rate α β⁄ ). In proton therapy a generic RBE=1.1 is 
applied instead of W012) and become D012) = D × 1.1, this expression called an RBE-weighted 
dose (the product of RBE=1.1 and the physical dose), units of biological dose Gy(RBE) which 
takes into consideration the biological effectiveness of the radiation type. The Figure 6 shows 
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the variants in the depth-dose curve of physical/absorbed dose VS bio-effective/isoeffective 
dose (Andre Wambersie et al., 2006; André Wambersie et al., 2011). 
 
 
Figure 6. The solid line represents the physical dose and the dotted line represents bio-effective 
dose/RBE-weighted dose corresponding dose weighted for radiation quality (RBE=1.1) (Beahrs & 
Henson, 1992). 
 
Relative biological effectiveness, RBE, in proton therapy has been based on the use of 
generic RBE of 1.1 within tumors and normal tissues, ignoring the generic value RBE=1.1, 
not constant, and it is dissimilar on this value as Figure 6 shows since RBE depends on 
factors as mention above, by the article of Paganetti found the RBE =1.1  at the entrance of 
beam and RBE=1.3, RBE=1.7 at the distal edge and distal fall-off region respectively, the 
RBE value increases at the distal range of proton beam which leads to increase the biological 
effect in the distal range of the dose deposition and it corresponding to the energy decreases. 
This effect can be express by the concept of the RBE-weighted dose, where reference to the 
product of the RBE and physical dose. (Anferov & Das, 2015; Harald Paganetti, 2003; 
Harald Paganetti et al., 2002). 
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2.4.5 Spread-out Bragg peak and dose deposition 
 In Figure 7, shows the difference in the way deposited dose of protons compared to the dose 
of photons in the target (tumor). For protons, the dose is low at the entrance and increases 
until the longitudinally narrow Bragg peak is reached (Mono-energetic and Multi-energetic 
proton state), followed by trivial dose distal fall-off beyond the Bragg peak with avoiding 
healthy tissue for the dose and it does not suitable for treatment to volume target whole, 
instead of that uses the concept of spread-out Bragg peak to cover the required target. For 
photons, the largest dose deposited in near-surface tissue, and even after the traversing 




Figure 7. Illustration of depth-dose curves for proton, photon, and SOBP beam (Zhu & Yoon, 2013). 
 
2.3 Radiation Biology  
The ability of ionization radiation to kill and destroy cancer cells without surgical 
intervention aroused widespread interest in the medical community. Destruction of a cellʼs 
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years, this program refined and expanded these techniques 
while treating 93,452 patients until January 1, 2013 2. PT 
is used today to treat many cancers and is particularly 
appropriate in sites where treatment options are limited 
and conventional radiotherapy presents unacceptable 
risks to patients. Because PT targets tumors better than 
traditional treatments, it is ideal for the treatment of 
tumors that are located near a vital organ. These sites 
include brain cancers, tumors close to the brain stem 
or spinal cord, head and neck cancers, eyes, inner ears, 
prostate cancers, and pediatric cancers. Recent studies 
have also shown the key impact PT can have on lung 
tumors, a medical condition that is today poorly treated 
with conventional radiation therapy. Today there are 
39 PT facilities in operation worldwide and 20 more 
under construction or planned, representing merely 
0.8% of all conventional radiotherapy systems. This is 
now an important tool to treat cancerous tumors 2. The 
technology is still advancing, with a number of research 
groups developing new ways of delivering protons more 
effectively and economically. By 2017 there will be 255 
operational PT treatment rooms 1.
PT is a precise form of radiotherapy which is currently 
unavailable in the Iran. The aim of this literature review is 
to evaluate of PT for brain tumors and spinal disease and 
is also to explain the need for this system in Iran based 
on cost-effective new generation, and medical excellence.
METHODS
A brief introduction to physics of proton therapy
PT employs a cyclotron; which is a nuclear reactor 
that can smash atoms to release proton, neutron, and 
helium ion beams. Protons are accelerated in a cyclotron 
to a speed equal to approximately half the speed of light. 
This also determines their energies, between 60 and 250 
MeV, and enables them to damage tumors up to a depth 
of about 30 cm. The protons are then targeted with a 
strong magnetic field into a very narrow beam - a pencil 
beam - and transferred with a high degree of accuracy 
via a 3D image to a target, such as a malignant tumor. 
The energy is released during deceleration in the tumor 
tissue with subsequent ionization and damage of the DNA 
of the affected cell. If the damage is sufficient, the cell 
stops dividing and growing or dies immediately 3.
Physics of proton therapy compared to photon 
therapy
Similar to conventional radiotherapy, PT is an external-
beam radiation therapy technique. It is one of the most 
precise modalities of external radiation therapy. Unlike 
a photon beam which has a high entrance dose and 
decreases gradually while passing through the body, a 
proton beam can penetrate through tissues and deposit 
most of its energy near the end of its track, known as 
the Bragg peak (Figure 1) 4. The energy from proton 
beam is released during deceleration in the tumor tissue 
with subsequent ionization and damage of the DNA of 
the affected cell 4. In clinics, a spread-out Bragg peak 
(SOBP) field can be generated by using protons of 
multiple energies 5. The rationale of using protons is 
based on the favorable depth–dose distribution, so that 
the targets can be located on a SOBP while the normal 
tissue is exposed in the plateau region 6. Compared to 
the conventional photon therapy, PT has a much lower 
entrance dose and no dose beyond the target volume. 
Because of this unique depth-dose characteristic, proton 
therapy is able to deliver highly conformal radiation 
fields to target volumes. Therefore, it is preferred for 
tumors with irregular shapes and/or around critical 
structure. Also, because of its much lower integral dose 
(approximately 60% lower than in photon therapy) 5, PT 
may provide some advantage for the treatment of pediatric 
patients, when the probability of secondary tumor caused 
by radiation dos to t  normal tissue is a concer . F r 
these reasons, the number of proton therapy centers is 
growing rapidly worldwide despite the high capital cost. 
Several companies are currently developing compact 
proton treatment equipment, which is expected to greatly 
reduce the cost of proton therapy. There are currently 
37 proton therapy centers in operation and over 25 in 
development. Worldwide development of proton therapy 
centers is rapidly increasing to meet patient demand 
(Figure 2) 7. In addition, PT was suitable for large-field 
radiotherapy, compared to traditional radiotherapy based 
on the relative biological effectiveness (RBE) 8. PT has 
become a trusted method for accurately targeting tumors 
and minimizing damage to healthy tissues, thus having 
Figure 1. The comparison of dose-depth profiles for photon and proton 
therapies, which was derived from reference 5.
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DNA completely is the certain cell death and an inability to proliferate, the ionization 
radiation has the ability to two different damage direct and indirect action (damage) types to 
DNA. Charged particles are capable of either direct damage of DNA by a single-strand break 
(SSB) or a double-strand break (DSB) as Figure 8 illustrates. Through SSB the cell's DNA 
can be repaired easily contrary to a DSB where DNA is unable repair and be harder to 
proliferate. The SSB type can have same impact as DSB if damage site occurs near short 
distance of each other. The other capability is indirect damage by producing free radicals 
across reaction with the water within the cell and it caused damage to adjacent DNA. 
Approximately 70 % of the proton energy loss be moved up delta-electron production and 
may be able to contribute to ionizing which lead to further strand breaks DNA. The indirect 
damage dominates through a low LET value and as a LET value increases the direct damage 
influence becomes conspicuous(Baskar, Dai, Wenlong, Yeo, & Yeoh, 2014). 
 
Figure 8. Radiation process of direct/indirect action (Baskar et al., 2014). 
 
 
2.3.1 The Linear-Quadratic model  
The linear-quadratic model is part of important tools in radiobiology, it describes the 
relationship between the delivery dose and the promotions of cells that survive in accordance 




s = e345 + e365! 
 
Where S is the cell survival, D represents the exposure dose and α and β represents the 
linear and quadratic parameters respectively, and these describing the cellʼs radiosensitivity. 
Through cell survival plotted on a log scale it gives a quadratic response curve as a function 
of dose as depicted in the figure 9. This shows the two components to cell killing, αD-cell 
killing (irreparable-cell) and βD2-cell killing (reparable-cell) combine to form a cell survival 
curve. 
α/β ratio is the dose at which log surviving for αD linear-component andβD2 quadratic-
component of cell killing are equal and it depends on radiation tissue type, for the specific 
tissues represents the ratio of essential radiosensitivity for it to repair capability, is given in 
Gy unit. Tumors and early responding tissue usually have a high α/β value between 7~10 
Gy, and late responding normal tissue usually have α/β value from 3 to 5 Gy. As Figure 9 
shows, the late responding tissue is more curved than early responding tissue and this leads 




Figure 9. On the left side the survival curve for linear and quadratic components and the displays of 
α/βratio point, on the right side the survival for high and low α/βratio (Balagamwala et al., 2012; 
McMahon, 2018).  
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2.3.2 Linear energy transfer and analytical models 
The side effects of radiation impact the quality of life of patients treated with radiotherapy 
and lead to normal tissue complications. The concept of linear energy transfer includes the 
perception of potential biological damage to the target through one of the radiation types 
used in radiotherapy. 
The irradiation causes biological cell damage proportional to the deposited energy of 
radiation in the target. The biological effects of ionizing radiation rely on some factors like 
the kind and size of the target and the radiation properties, for the same energy, heavy 
particles (alpha particles, proton, and neutron) deposit their energy for a much shorter 
distance than gamma rays and X-rays. The linear energy transfer is proportional to the 
velocity and the charge of ionizing radiation; accordingly, it increases the charge velocity 
(kinetic energy) decrease and as the charge of ionizing radiation increases as illustrated in 
Figure 4 and 2, this corresponds to lethal effects and the relative biological effectiveness 
(RBE) increase as the LET increase, look over at Figure 5. At the same time, at the distal-off 
dose corresponding to a high value of LET as Figure 10 shows. Table 2 below shows LET 
values for different radiations types (Beyzadeoglu, Ozyigit, & Ebruli, 2010).  
 
 






Table 4.LET values for different radiations types (Beyzadeoglu et al., 2010). 
 
The charged particles lose energy as they traveling through the medium by inelastic 
interaction with atomic electrons as described by Bethe-Bloch formula. Zirkle described the 
absorbed energy by the medium as the linear energy transfer (Zirkle, Marchbank, & Kuck, 
1951), LET, of charged particles measures the energy absorbed (dE) by medium per unit 





It used to quantify the effects of ionizing radiation on biological samples (Breuer & Smit, 
2013). High-LET deposit more amount energy per unit path of the target more than the 
same dose of low-LET (which deposit less amount of energy) high-LET cause significant 
DNA damage (Beyzadeoglu et al., 2012). It considered low-LET radiation when the LET 
below  10		 keV/µm, while above 10	 keV/µm is regarded as high-LET radiation (Park & 
Kang, 2011). 
Actually, the concept of LET is a similar description of the stopping power,S, the exclusion of 
the effects of radiative energy loss, for instance, Bremsstrahlung or δ-rays (Park & Kang, 
2011). The linear energy transfer is defined by ICRU report 90 as the restricted LET 










 Where dE7 the energy lost by charge particle due to inelastic interaction with atomic 
electrons minus the aggregate of kinetic energy for electrons liberated with kinetic energy 
dE8!,7 > Δ by charged particles over a track, dx , and S!" refer to linear stopping power 
(Baltas et al., 2006). Δ represents energy cut-off, expressed by eV, not range cut-off although 
the restricted linear energy transfer represents the energy loss locally imparted (Units, 
1998). 
The LET called unrestricted energy transfer, L9, in case contains δ-rays and all electronic 
interactions and ignored the energy cut-off, then L9 = S!"	and it is equal to electronic 
stopping power concept and been used to calculate the absorbed dose for this case, as shown 
in Figure 2, displays the relation between the LET of protons and the kinetic energy of 
proton (Tsuboi, 2020). 
The calculation of LET is easily reached in regard to monochromic beams due to the clearly 
defined kinetic energy, there various considerations that are needed for non-mon-energetic 
in which calculation of  L9 shows more complex (Wilkens & Oelfke, 2003). 
Protons in the substance are subject to Coulomb interaction and nonelastic nuclear 
interaction, the non-elastic nuclear interaction takes place frequently in the entryway of the 
Bragg curve and the value of LET tends to be small and slightly different. The commonest 
interaction process is the Coulomb interactions of primary protons are considered and it 
takes this into consideration for an analytical LET model, mostly at the distal edge and 
around the crest of Bragg curve which corresponds to an increase of LET, the absorbed dose 
is affected through this interaction. The dose behind the Bragg peak which come from 
secondary particle can be neglected (H Paganetti, 2002; Wilkens & Oelfke, 2003). 
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The international commission on radiation units and measurement (ICRU) introduce two 
different concepts of LET to the track-average LETt (the track divides into equal length and 
the energy average deposited in each length), and the dose-average, LETd (the track divides 
into equal energy and averaging the track length deposited these energy in the track length) 
("Report 16," 2016). The dose-average, LETd, has become of regard in use into the 
treatment planning system and biologically effects (Grassberger & Paganetti, 2011). The 
LETt defined as the mean value, arithmetic average, S for all protons weighted by fluence, 
while the LETd for every single proton is weighted by it is contributions to the local dose. 
In order to figure a mean of LET for every kind of particle independently, utilizes the 
stopping power and energy spectrum then take the total of their average to get total LET 
(Wilkens & Oelfke, 2003). Both of LETt and LETd depend on the local energy spectrum at 
the point/place x. It can describe the spectrum with reference to residual range of particle by 
the concept of the continuous-slowing-down approximation (CSDA) which gives the relation 










where r indicates to the residual range at the point x, φ#(x) the local particle spectrum at the 
point x, S(r) the stopping power of primary protons into residual range r and, φ#(x)dr 
represent the fluence of protons at the point x with residual range within r and r + dr.  












In the case of the monoenergetic protons, both LETd and LETt equivalent the stopping 
power S. The equations above for, LETd and LETt represent for single beam of proton, for n 
beams with the local fluence spectra φ#,<(x) at the point x, the track averaged, LETt, and the 


























2.3.3 Relative biological effectiveness 
Relative biological effectiveness, RBE, is determined as the ratio between standard radiation 
dose, X-rays or gamma-rays, to the test radiation dose to cause the same biological effect 
goals, it is evaluating or/and compares the biological effect of a specific type of radiation with 
a standard radiation. In proton therapy, all treatments are performed with an RBE of 1.1 
without regard to depth in the tissue, cell kinds, dose per fraction, dose rate and biological 
endpoint, this presumption was determined from past experimental data basically gotten at 
the middle of SOBP. RBE is a complicated conception to match the standard radiation with 
the test radiation in the same circumstances due to the RBE relies on many factors such as 
dose per fractions, LET, cell kinds, endpoint, exposure conditions, and the energy of 
particles. 
Experiments indicated that LET and RBE are exceedingly related, where the latter increasing 
as LET be increasing in certain limits, it has been observed RBE values decrease at LET 
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surpassed 100 keV/μm. Beyond this LET value, the RBE inclines because of cell overkill. 
This is due to high LET particles densely ionization executed on the cell, DNA, that is 
required for DNA damage. Proton particles impact to clustered DNA damage more than 
photons. As the Figure 11 shows this tenor(Willers et al., 2018). 
 
 
Figure 11. Illustration of positive relationship of RBE and LET, and shows how protons product of 
cluster DNA damage cluster compared to photons (Willers et al., 2018). 
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3. Patient Data and Treatment Planning 
Treatment planning systems (TPS) are the core of the radiation therapy (RT) systems, and 
the tool to enhanced patient upshots, through patient images and identified the tumour, TPS 
construct an integral plan for each beam track to deliver the treatment, dose, to the tumour 
appropriately. 
The primary challenge is to form a plan delivered high dose to the tumour conveniently and 
minimize the healthy tissue and organs at risk of high dose radiation concurrently, there are 
several systems in use the treatment planning systems, for instance, Brainlab, Elekta, Philips, 
Prowess, Raysearch and Varian Eclipse, the latter is used in this thesis (FORNELL, July, 
2013). 
3.1 Digital Image Acquisition 
The treatment planning requires the patientʼs images to be of high accuracy and taken 
correctly according to the patientʼs position in order to make it possible to estimate the 
location and dimensions of the tumour additionally to potential organs at risk, in addition to 
helping to obtain information about tissue density that helps to make accurate calculations of 
dose distribution. 
The medical imaging modalities utilized are several and variety like positron emission 
tomography (PET), ultrasound (US), magnetic resonance imaging (MRI), and computed 
tomography (CT). The CT provides tissue density information and represents the gold 
standard in radiotherapy (Khan & Gibbons, 2014). 
The computed tomography (CT) scan consists of a series of X-ray images extracted from a 
different angle, in which X-rays are geared toward and rapidly rotated continuously at the 
body patient in a helical shape called a gantry, the X-rays exits of the patient body and 
39 
 
capture by detectors, the machine's computer processes the signals come from the detectors 
and assists to create cross-sectional images (slices), as soon as several successive slices are 
collected by the machineʼs computer simultaneously it lead to form a three-dimensional 
image of the patient and allows to designation the location of basic structures in addition to 
potential tumours(Smith & Webb, 2010). The principle of CT is based on the intensity of 
photons penetrating medium can be calculated by the equation: 
 
I = I;e3?* 
 
Where I is the amount of photon intensity after crossing the medium, I; is the primary 
photon intensity, µ is the linear attenuation coefficient which represents the number of 
photons absorbed per cm, and x is the thickness of the absorbing medium. The attenuation 
coefficient relies on the density of penetrate the medium. Therefore, the grayscale is used  in 
X-ray images to describe the different attenuation according to the attenuation scale, in 
which the darker areas on the X-ray image correspond at occurred less attenuation on low 
relative density regions, at the high relative density where highly attenuation the brighter 
areas appear (Khan & Gibbons, 2014). 
3.2 The Hounsfield Unit  
The grayscale CT images as it appears in the figure were placed by using the Hounsfield 
Unit (HU) also called CT number to regions has variant attenuation of radiation as show in 
Figure 12, the HU is calculated based on a linear transformation of the linear attenuation 
coefficient of the X-ray and defined as: 
 






Where, water is defined to have HU = 0, HU = 1000 to dense bone and HU = −1000 to air, 
the linear transformation produces a HU scale that displays grayscale. In order of maximal 
photons absorption in more dense tissue, the HU has positive values and seems bright, with 
regard to minimal photons absorption in less dense tissue, the HU has negative values and 
seems dark. In proton therapy, the range of protons can be calculating by converted the HU 
into relative stopping power values(Ainsley & Yeager, 2014). 
 
Figure 12. Hounsfield number for various human tissues (Kalra, 2018). 
3.3 Volumetric and Target Delineation 
The development in computer technology during recent decades, which helped in the 
possibility of planning the dose of radiation therapy in three dimensions and radiotherapy 
treatment, leads to the need to insert specific definitions for each tumor and the areas of 
potential spread were presuppose. According to the methods mentioned above to get 
patientʼs image, each of the targets and volumes utilized to treatment by radiation therapy 
had been defined in ICRU Report 50(D. Jones, 1994). 
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3.3.1 Gross tumor volume (GTV)  
GTV is defined as a visible/palpable tumor by imaging the tumor using modern diagnostic 
imaging modalities such as PET, MRI, or CT, the GTV be formed of the primary tumor and 
high cell density and therefore sufficient dose must constantly be delivered to the whole 
volume for therapy(Harald Paganetti, 2018). 
3.3.2 Clinical target volume (CTV)  
The GTV is just not the main malignant region only, often includes extends from the main 
malignant in the form of individual malignant cells or small malignant cell bunch that is hard 
to be clinically noticed. So, the CTV included the GTV region in addition to these extended 
tumor cells(Harald Paganetti, 2018). 
3.3.3 Planning target volume (PTV)  
Once the entire macroscopic tumor became delineated, must be taken into account the 
patient movement or placement of the malignant cells on the nearness of the organ motion 
for instance lungs and heart. To guarantee the suitable treatment of the whole CTV. The 
planning target volume (PTV) can extend beyond CTV and takes such potential problems 
into account by adding a margin of these considerations around the CTV. The PTV is used 
for handling dose prescriptions to guarantee delivery of the prescribed dose to the whole 
CTV(Barrett, Morris, Dobbs, & Roques, 2009; Harald Paganetti, 2018). 
 
3.3.4 Organ at risk (OAR)  
Once making radiation treatment of a patient, the treatment planning should be included the 
organs where have sensitive to radiation that they can greatly impact the treatment planning 
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or the prescribed dose, these sensitive organs should be delineated and be called organs at 
risk (OAR)(Tsuboi, Sakae, & Gerelchuluun, 2020). Figure 13 below illustration the 
delineated of these various target volumes. 
 
Figure 13. The right side represents lung cancer radiotherapy and the sketch of the left side the 
treatment volumes where, irradiation volume (IV-purple), treated volume (TV-green), planning 
target volume (PTV-blue), clinical target volume (CTV-red), gross tumor volume (GTV-yellow) and 
organs at risk(OAR)(Hyun Mi Kim, 2018, Feb). 
3.4 Plan Assessment of Radiotherapy 
The objective of radiotherapy is to deliver the appropriate dose to the target and avoid the 
normal tissue and organ at risk. Ways of estimating the treatment plan can be achieved through 
different methods. The dose distribution and volumetric are analyzed and examined using 
dose distribution showing and dose-volume histograms. 
3.4.1 Dose-volume histograms 
Dose-volume histograms (DVH) relates dose of radiation to tissue and/or organ volume in 
treatment planning as a histogram. The DVHs are mostly widely utilizing to put it briefly the 
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simulated dose distribution inside a volume of interest of a patient which would result from a 
suggested treatment plan and/or to compare doses from various plans. (Drzymala et al., 1991). 
3.4.2 Dose distributions 
The dose distribution may become optically examined utilizing color wash added on the CT 
images. The color wash displays the dose distribution color bar clearly defined, where generally 
the cooler colors describe the lower dose, and the warmer colors describe the higher dose. 
Whereas the presence of dose accordance with the color wash form over the CT images gives 
an easy and logical impression of how the dose is dispersed, it tends to be hard to appropriately 
assess treatment plans as far as the measure of dose organs and targets that irradiated(Brady, 
Heilmann, & Molls, 2006). 
3.5 Treatment Delivery and Accelerators 
3.5.1 Accelerators and energy modulation 
In particle radiotherapy usually utilized accelerators to achieve the energy of particle required. 
In proton therapy, the two main types of accelerators; the cyclotron and the synchrotron. An 
energy required for radiation depth of 30 cm in tissue by protons about 230-250 MeV using 
the accelerators mentioned above. A cyclotron consists of a pair metal flat of semicircular shape 
called 'Deesʼ; the particle charged source (source of ions) injected among the center of the gap 
between two Dees. Under high-frequency alternating voltage and magnetic field, the particles 
are accelerated in an outward from the center along a spiral path until they reach the as much 
energy allowed by the cyclotron, at that moment they are extracted. However, one limitation 
of the cyclotron does not operate when charge particles gain extremely high speeds, the mass 
increasing as the speed increasing and this leads the charge particle take long time to complete 
the semicircular track inside the dee, it is unable to accelerate these particles further, so 
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synchrotron comes that can accelerate charged particles beyond a relativistic speed and not 
suited for ions heavier than protons. The advantage of a cyclotron is the ability to produce a 
continuous beam of particles, where is unable to execute by a synchrotron. In return, the 
disadvantage of a cyclotron is the fixed energy of accelerator particles required. Cyclotrons can 
accelerate protons until the energy range of 230-250 MeV and by using energy modulation to 
achieve lower energies through degrader as against the beam after extracting or inside the 
treatment nozzle itself, this called passive-modulation(Brady et al., 2006; Coutrakon, 2007).  
 A synchrotron is considering large machine compared to the cyclotron, using a linear 
accelerator for charged particles before entering the synchrotron, the synchrotron made-up 
of a circular form of a long-evacuated tube with robust magnets utilized for bending the 
particle charged path and for focus the beam. The energies at which the particles are 
accelerated can be changed within the accelerator by controlling the magnetic field strength, 
which is called active-modulation. The illustrations show a simplified schematic of 14(a) 
synchrotron and 14(b)cyclotron.   
 
Figure 14(a). Simplified schematic of synchrotron 
(Godfrey, 2018). 
 
Figure 14(b). Simplified schematic of 





3.5.2 Techniques of beam delivery 
The aim of particle therapy is the dose to be conformed to the destination volume, a 
monoenergetic beam give longitudinal tiny Bragg peak where is unhelpful in the treatment, 
the active and passive modalities mentioned above spread the beam to the destination volume 
in the longitudinal direction(depth-dose), to fill the whole target volume in the lateral 
direction, there are two methods have been using in order to spread the beam are names the 
pencil beam scanning (PBS) and passive scattering (PS) (Mayles, Nahum, & Rosenwald, 
2007). 
Passive Scattering 
Passive scattering (PS) is considered an old technique particle therapy, to achieve of lateral 
direction of the narrow particle beam according to the lateral dimension which required, 
usually by using a single scattering with one scatter foil in order to small field are or by double 
scattering through using two scatter foils, the treatment beam can be formed based on the 
target volume required using a tool called collimators to use for each individual treatment 
beam. The collimation tool may take place an additional dose to the patient due to the 
interaction properties of the collimator material with the treatment beam via secondary 
radiations, which gives the disadvantage to the passive scattering technique(Mayles et al., 
2007). In Figure 15a shows the passive scattering techniques details. 
Pencil Beam Scanning  
Pencil beam scanning (PBS) or as called scanning beam is the most precise in proton 
therapy treatment. PBS is involved sending a narrow proton beam through utilized a pair of 
magnetic dipoles of the X-axis and Y-axis to handle deflect and distributing the beam directly 
to the target volume as required in the lateral direction and can achieve various depths of 
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dose deposition by altering of the energy where enable control of dose distribution without 
the assistance of passive components and that leads no additional dose to which result comes 
from secondaries radiation. Consequently, the target volume can be scanned by the beam 
each slice of the target separately. The beam scanned kind determines according to the 
irradiation treatment demand for one layer of voxels or in order to each voxel separately. The 
Pencil beam scanning can be dose conform for the proximal and distal end of the target 
therapy helps to avoid the high doses to normal tissue which is an advantage for PBS(Mayles 
et al., 2007). Pencil beam scanning is shown in Figure 15b. 
 
Figure 15a. Illustration of the passive scattering (Wang, 2015). 
 




4. Simulations of Dose and LET 
The information technology makes a great contribution in therapeutic and diagnostic 
applications of ionizing radiation (Grassberger & Paganetti, 2011). The Monte Carlo, MC,  
technique has become omnipresent in medical physics in recent decades because of increase 
interested of particle interaction and transport in the medium and help of dosimetric 
calculation in radiation therapy from internal dosimetry of nuclear therapy and help to the 
treatment planning in external radiation to estimate the distribution of radiation dose in 
contrastive medium e.g. lung and bone (Amato, Lizio, & Baldari, 2013; Verburg et al., 2016).  
In proton therapy, many Monte Carlo codes are used, for instance, Geant4, FLUKA, EGS, 
and MCNP, these codes vary in accuracy small difference  in the user interface, and vary in 
grade of control onto tracking parameters (Amato et al., 2013; Seco & Verhaegen, 2013). 
MC simulation is utilized to model the probability of various results in a process that difficult 
to predict due to the interference of random variables. It is a procedure used to understand 
the effect of risk and uncertainty in prediction models, and also gives a thought of what 
results to expect as well as the likelihood of the event of that result. This feature made a lot of 
fields and branches to use MC simulation like physics, statistics, and finance (Amato et al., 
2013). 
4.1  FLUKA 
FLUKA is one of MC code (Böhlen et al., 2014) and is a multipurpose in numerous fields, 
and capable of study 60 various particles, which be good consider to simulate for 
electromagnetic and hadron particle interaction and transport in any target through a broad 
energy domain (Ferrari, Sala, Fasso, & Ranft, 2014). The electromagnet and muon 
interaction can be simulated up to 100 TeV, the hadron interactions up to 100 TeV. The 
code has the potential to track particles in the magnetic and electric field and simulate the 
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optical photons (Giuseppe Battistoni et al., 2011). The graphical user interface, called Flair, 
supports to use for FLUKA Monte Carlo code (Ferrari et al., 2014). FLUKA depends on 
original and all-around tried microscope models. Improves consequence FLUKA model 
performance and make it more realistic and accurate through comparing with experimental 
particle production data at single interaction levels (Giuseppe Battistoni et al., 2011). 
4.2 Eclipse 
The Eclipse treatment planning system, Eclipse (TPS), is a treatment planning software 
utilized to plan external beam irradiation with photon, proton and electron beam. Since the 
treatment therapy system generally contains beam production region, delivery beamline 
system, and treatment machine area (nozzle), Eclipse binds between the treatment machine 
and a treatment planning system and gains information used for treatment planning from the 
patient's CT image and from the compared databases at treatment machine at site. It 
includes a variety of treatment templates that help simplify the process of creating 
customized treatment plans for each patient and that to save time instead of building a plan 
from the starting point, where the Eclipse enables the specialist to modify formerly set up 
treatment according to a requirement of treatment. The three-dimensional dose calculation 






5. Methods  
The main purpose of this project was to calculate the LETd for water phantoms and patients 
by using both the FLUKA MC code combined with in-house scripts from our research group 
(Fjæra, 2016) and the Eclipse prototype estimator for LET which uses an analytical LET 
calculation script which is integrated into the Eclipse software. An additional aim was to 
compare the LETd from the two methods in terms of LET volume histograms and LET 
metrics as well as colorwash plots of LETd distributions in the phantoms and patients. In the 
final phase of the project, RBE-weighted doses (biological dose) were also calculated to 
estimate the impact of different LET calculations on the final estimated RBE-weighted dose. 
The data of the treatment planning system are sorted as DICOM file format and was 
extracted from existing treatment plans and translated for simulations in FLUKA and further 
analyses and visualized utilizing Python (v2.7) programming language and the Slicer 
software (v4.11.0), a software platform used for visualization and medical image computing. 
Python was used to visualize two-dimensional dose and LET distributions while Slicer was 
used to plot Dose-volume histograms. 
5.1 Simulation Process of Water-Phantom dose plans 
The water phantom plan and dose distributions were generated in the Eclipse treatment 
planning system for proton therapy. The water phantom was a 30 x 30 x 30 cm3 water 
volume, with a 4 x 4 x 4 cm3 target volume (PTV) located in the center of the phantom. The 
plan consists of two opposing proton beam fields with energies ranging from 103 to 132 
MeV, and a dose prescription of 2 Gy (RBE1.1) to the PTV. The simulations were executed 
using the proceedings shown in Figure 16 and described in detail in section 5.3.  
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5.2  Simulation Process of the Patient Treatment Plan 
A brain tumour case was applied, with a treatment plan and dose distributions created in the 
Eclipse treatment planning system for proton therapy at Haukeland University Hospital. The 
plan composes of two opposing fields, where the beam energies of the first field had a range 
of 70-125 MeV with a gantry angle of 270⁰ and the second field had energies ranging from 
81 MeV to 131 MeV with a 90⁰ gantry angle. The total number of protons for two fields 
combined was 1.29×1012. The plan had a prescribed dose of 54 Gy (RBE) to the PTV, 
delivered in 30 fractions.  
Figure 16 shows the steps that have been done to execute the FLUKA simulations and 
additional scripts, according to the process created from our research group (Fjæra, 2016). 




Figure 16. Illustration for implementing patient treatment plans in FLUKA MC recalculation 




The FLUKA recalculation scripts are used to recalculate treatment plans from the Eclipse 
TPS at the Haukeland University Hospital bound in Bergen for IMPT. In addition to enable 
Monte Carlo simulations, these scripts can be used to plot dose-volume histograms, compare 
dose, RBE, and LET. These scripts were in this project used together with the FLUKA 
version (v.2011.2c.4) and the FLUKA graphical interface Flair (version 2.3), both operated 
by Unix based systems (Mac OS and Linux). The FLUKA simulation recalculation was 
enabled and done by using the scripts as described in the following sections. 
5.3 DICOM File Handling and Generation of FLUKA Input File  
After a treatment planning system has been applied to calculate and evaluate a treatment 
plan, the DICOM files (yellow boxes in Figure 16) containing the treatment information, 
including the dose profiles, structures, and patient images, were exported through the script 
called Sort_dicoms_impt.py. This script was used to build the files that are needed for the 
FLUKA recalculation of dose and LET. This script creates the environment necessary for 
executing recalculations, in simple terms, the DICOM files that the user got from Eclipse-
IMPT-plan has been sorted inside a folder which includes some files needed to recalculate 
each single treatment plan separately: 
• CT images of patient. 
• RT Structure ‒ Coordinates and colors of delineated structures 
• RT Plan ‒ details of the treatment plan itself for example proton beam spots, gantry 
angle. 
• RT Dose ‒ Includes information regarding the delivered dose to the patient, Where the 
user has single file of RT Dose for each treatment field separately, and one file for all 
treatment fields combined. 
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At same time, this script creates files used it in the input of FLUKA recalculation, these 
data concerning about: 
• Maximum number of regions in FLUKA‒ 5000. 
• Source routine card needed for source.f routine which defines the primary beam 
properties 
• Physics settings HADROTHErapy (described below). 
• Momentum spread for General Cap Machine in Eclipse at Haukeland ‒ 0.9%.  
• Voxel card containing the patient position in the FLUKA coordinate system. 
• USERWEIGH card needed for fluscw.f routine which is used for dose and LET scoring 
• Scoring cards, where bin 40, 41 and 50 has been used and based on the fluscw.f 
routine ( the primary Monte Carlo tools calculate dose-to-material and fluscw.f 
routine used to calculate dose-to-water) and all LET are the unrestricted LET,L9,in 
water where: 
• Bin-50 represents deposited of Dose-to-water from all particles (LET × fluence). 
• Bin-40 represents deposited of Dose-to-water from all protons only (LET × fluence). 
• Bin-41 represents deposited of Dose-to-water from all protons only from all protons 
only multiplied with electronic stopping power,	L9 = S!" ,(LET2 × fluence). as 
Figure 17 shows below. 
• a .dat file is generated and contains information (beam directions and energies, spot 





Figure 17. illustrations of BIN and USERWEIG card on FLAIR. 
 
5.4 Setting HU Units  
The script set_HU.py was operated and used to set a Hounsfield unit of -1024, which 
represents vacuum, outside the patient (for consistency with the TPS dose calculations) in 
the CT images. The CT images were then used to generate a voxel file(.vxl), which gives 
information of the CT in FLUKA.  
5.5 Running the Simulation 
5.5.1 DEAFULTS card 
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Prior to the initiation FLUKA simulation, FLUKA gives a category of default physics settings 
miscellaneous, helping the user to select and choose the appropriate setting for particular 
applications and in turn to define what FLUKA appropriate defaults to be utilized for 
recalculation condition. In this project the HADROTHErapy DEAFULTS card has been 
used for water phantom plan simulation and patient treatment plan simulation shows in the 
Figure 18, as this is recommended for particle therapy applications. Functions framework of 
this kind of card are: 
§ Δ-ray production on with threshold 100 KeV. 
§ Neutron threshold for high energy at 20 MeV. 
§ EMF (ElectroMagnetic FLUKA) on. 
§ The threshold for primary and secondary charged particles of Multiple scattering at 
minimum allowed energy. 
§ In elastic Compton profiles and Compton scattering active. 
§ Hadrons/muons and EM particle ionization fluctuations are restricted on. 
§ Tabulation ratio for hadron/muon dp/dx set at 1.03, fraction of the kinetic energy to 
be lost in a step set at 0.02. 
§ Fully analogue absorption for low-energy neutrons (below 20 MeV).  
5.5.2 Source card 
This card reads the Source.f routine, in Figure 18, which contains information of energies 
used in the TPS, patient position as well as the Gantry angle, and all spot information used 
in the treatment, i.e. the spot weight, sizes, and positions.  
All this information has been extracted from the PBS DICOM plan by using the 
Sort_dicoms_impt.py script. 
5.5.3 USERWEIG card 
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Treatment planning systems normally calculates and reports dose-to-water as this is the 
standard form of reporting dose in radiotherapy(Harald Paganetti, 2009). In contrast, 
FLUKA MC calculates dose relying on material scoring, which initially makes comparisons of 
dose between the two systems hard. Through the fluscw.f routine we can however achieve 
the scoring of dose-of-water also in FLUKA by using the USERWEIG card as Figure 17 






DA, represent Dose-to-water. 
Φ,, charged particle influence in a given medium. 
LETA, linear energy transfer in water. 
ρA, water density. 
5.5.4 Voxel card 
A detailed patient geometry is described in practice in the shape of voxels, via three-
dimensional grid space. Each voxel composed of material and density information of patient 
geometry and it is memorized in voxel files. FLUKA is able to process voxel files using a 
VOXEL card, which is created from DICOM CT images using the Flair graphical user 
interface.  In this project, the voxel file was determined after using the set_HU.py script over 




Figure 18. Illustrations of DEFULTS and SOURCE cards on FLAIR. 
5.1.1 Simulation resources and data processing 
5×106 primaries for 24 parallel simulations have been used for each treatment beam field, 
giving a total sum of 1.2×108 primary protons. The whole CPU time period to achieve 24 
parallel simulations was 4 hours for a single beam field only and for to two beams filed 
combined it was 8 hours.  
Each treatment field used 5×106 primaries for 24 parallel simulations, in order to execute a 
total of 1.2×108 primary protons. A total duration CPU time in order to do 24 parallel 
simulations was 27 hours, and for two treatment beam fields the simulation took 54 hours. 
Once adding all settings required as referred above and after the simulation had been done, 
the parallel simulations were merged together into result files in the generic FLUKA format 
(.bnn-files). These were then converted to ASCII format (bnn.lis files) which finally could be 
used and converted to DICOM files. This was done utilizing the convert_to_dicom.py script 
(see Figure 16). According to the user request DICOM files contain various data can be 
58 
 
created based on which study required to handle of list below, for this project goal the 
information regarding data was chosen for the first two options from the list only: 
§ Dose-averaged LET (LETd) 
§ Biological dose (RBE = 1.1) 
§ Physical dose (RBE = 1.0) 
§ LET-weighted dose (C x LETd x physical dose), where C must be provided by the user.  
§ Neutron dose  
§ Biological non-linear models (Rørvik weighted, Mairani, and Belli). 
§ Biological linear models (Wilkens, Wedenberg, Caribe, McNamara, Chen, Frese, Jones, 
Tilly and Rørvik unweighted). 
5.8 Running LET estimation on Eclipse-Micro-Calcualtion 
The water phantom and patient plan were created and analysed in the Eclipse treatment 
planning system as Figures 19 and 20 shows, the dose calculated with regular pencil beam 
convolution superposition (PCS) algorithm (Version 15.6.06) in Eclipse. 
The Micro-Calculation script has been included in the algorithm, which can calculate various 
choices, for instance, calculate dose, LETd, Micro LETd, yD, and the RBE base on 
McNamara or MKM model. After running the scripts, it was utilized the options of 
calculating dose, LETd, and McNamara model for water phantom and patient treatment plan 
as seen in Figures 21 and 22. The LETd of the script is based on the unrestricted linear 
energy transfer calculated by conventional methods using a stopping power curve (not 
micro-dosimetry) and in this work it has been chosen due to the LETd calculated by MC 
FLUKA to the same patient plan was based on the unrestricted LETd also. Values were 
entered of the alpha/beta ratio for PTV and OARs is 10 Gy and 3 Gy for patient case 
respectively, in addition, the alpha/beta ratio for the PTV and body-water phantom is 2 Gy 
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used to calculate RBE by McNamara model as shown by Table 5 and in Image 23 and 24 for 
the water and patient case. 
 
Table 5. Alpha/beta ratio utilized for calculated RBE-MCN for all studied cases. 
Water Phantom        alpha/beta ratio Patient Case.             alpha/beta ratio 
PTV                                     2 Gy 
Body                                    2 Gy 
PTV                                    10 Gy 
Brainstem                            3 Gy 
Temporal lobes L                3 Gy 
Temporal lobes R                3 Gy 
Hippocampus L                  3 Gy 









Figure 19. A water phantom on Eclipse (TPS) for Field-1 and Field-2 on PTV region represented in 
the red cubic shape. 
 
 






Figure 21. Options Eclipse MC-script of water phantom. 
 
 
















 5.9 Visualisation and Extraction of Metrics 
5.9.1 Plot Dose-distribution 
In order to compare the dose distribution from the TPS and FLUKA, visualization of the 
distributions was obtained by utilizing the script named plot_dicom.py.  This script plots the 
TPS and FLUKA biological dose and dose distribution as two-dimensional(2D) color wash 
transported over a DICOM CT image, as well as plotting the difference of dose calculation 
from FLUKA and the TPS. 
5.9.2 3D Slicer 
The RT dose DICOM files extracted after the simulation, was used to plot Dose-volume-
histograms (DVH) through using an open-software for viewing medical images and 
informatics called 3D-Slicer (v.4.11.0). Slicer translates the DICOM CT image and enables 
the user to create the DVH of DICOM files(Pinter, Lasso, Wang, Jaffray, & Fichtinger, 
2012). 
5.9.3 Plot Dose and LETd volume-histogram  
Once the simulation had done, the data had been exported of dose and LETd data required 
to plot volume-histogram, VH, for all study plan, and for LETd VH, the data was extracted 
from Eclipse (TPS) software as DICOM format, the data of both used it in 3D Slicer to 




6. Results  
In this section, the results obtained from both the Eclipse-treatment planning system 
technique and the FLUKA MC recalculation technique will be displayed. This includes the 
dose, LETd and RBE-weighted doses of both the water phantom and patient treatment plan. 
In addition, an inspection of the differences in LETd and physical dose calculated with the 
FLUKA recalculation and with Eclipse Micro-calculation script and finally, a comparison of 


















6.1 Water Phantom results 
6.1.1 Comparison of RBE 1.1. dose 
 
Figure 25. Illustration a calculation of dose distributions in accordance with both FLUKA(RBE1.1) 
and Eclipse (TPS(RBE1.1)), A and B for Field-1, D and E for Field-2, G and H for All-Fields with 
shows the dose difference of them on the right side, the PTV is delineated with a red cubic shaped. 
 
Figure 25 shows the biological dose calculated with FLUKA(RBE1.1) and Eclipse 
(TPS(RBE1.1)) and the corresponding dose differences for the water phantom plan.  
The dose difference indicates small differences of dose calculate between of FLUKA and 
Eclipse (TPS) techniques, it can be observed that the PTV middle region in order to All-
Fields status the dose through the FLUKA technique is little higher than Eclipse (TPS) 
technique, at the same time the outer and inner rim of PTV region, it was observed the 
Eclipse had a little higher than FLUKA. In Figure 26 the dose-volume histogram is shown, it 
displays a little difference among V100% to V60% about less than 0.06 Gy of dose calculation in 
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connection with All Fields-PTV status for both techniques emphasizes. Thus, overall good 
agreement was seen for the dose calculation of FLUKA and the TPS, although a slightly 
lower dose was observed for the TPS. 
 
 
Figure 26. DVH of Eclipse (TPS), dotted-line, and FLUKA, solid-line, (both using RBE1.1) of Field-













































Figure 27. Dose-profile (DP) of Eclipse (TPS), light-blue line, and Eclipse Micro-Calculation, red 
line at PTV region, the left side represented DP before plan normalization, the right side 
represented DP with normalization of the Micro-Calculation plan. 
 
The dose profile at the PTV region as in Figure 27 of the left side shows variation between 
Eclipse (TPS) from 2 Gy(RBE1.1), light-blue line, and Eclipse Micro-Calculation, red line, on 






Figure 28. Illustration the physical dose of FLUKA and Eclipse Micro-Calculation script of PTV 
water phantom. 
Figure 28 illustrates a 2D comparison of physical dose distribution of water phantom 
calculated through FLUKA and Eclipse Micro-Calculation script after utilizing the re-
normalization plan, where the first row shows Field-1, the second row shows Field-2, and the 
last shows All-Fields.  
It shows in Figure 28 at the status of the separate fields gave value under 1 Gy value for both 
methods. According to the PTV region for all fields shows convergent distribution both less 
than 2 Gy. 
6.1.3  LET of Water Phantom 
The LETd distribution and LETd volume histograms of the water phantom are shown in 
Figures 29 and 30, respectively, and display a disparity among the FLUKA and Eclipse LETd 
values. Figure 30 demonstrates Eclipse is a bit higher than FLUKA throughout all fields, the 
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LETd of singular field from both methods below 7 keV/µm at distal range as Figure 29 




Figure 29. Illustration of LETd of Field-1, Field-2 and All-Fields row for PTV water-phantom 
respectively by FLUKA and Eclipse Micro-Calculation script. 
 
Figure 30. LETd VH of PTV water phantom by FLUKA, solid-line, and Eclipse Micro-























6.1.4 RBE McNamara model  
In this section, the RBE calculations from FLUKA and Eclipse Micro-Calculation script are 
presented for the water phantom plan. The RBE was calculated using the McNamara model,  
the alpha-beta ratio of 2 Gy was used in FLUKA and in Eclipse Micro-Calculation as 
mentioned in 5.8 section.   
 
 
Figure 31. Illustration of RBE-MCN model for PTV water-phantom for Field-1, Field-2 and both 
Fields by FLUKA and Eclipse Micro-Calculation script. 
 
The RBE values for both FLUKA and Eclipse increase towards the end of the beam, as seen in 
Figure 31. Field-1 and Field-2 represented by the first and second row respectively and give 
how differing the within the PTV region (red-cube) results of FLUKA and Eclipse calculation 
at RBE-MCN model. The RBE values Inside and back of the PTV were transparent for both 




Figure 32. The RBE values within the PTV region of water phantom, Y-axis represents the RBE 
values and X-axis the longitudinal direction in the core Field axis of PTV region. 
 
Figure 32 displays the RBE value within of PTV region where at the entrance of PTV, the 
RBE value is below 1.1 and start to increase up this value at the end of the PTV region, 
thereafter, the RBE value started to increase from 1.1 to reach RBE=2.3 at the front of PTV 
and with a low value on the side edges. About the FLUKA case, the PTV being roughly of 1.2 
and it increases further at the distal edge of the field at almost reaches a value under 2.3, 
with constant of this value on the side edges of PTV region. Furthermore, that RBE values 
within PTV for both fields of Eclipse and FLUKA have ranged from 1.1 to 1.3 and take 1.7 
roughly at both sides of PTV. By relating the results of both LETd and RBE, the high LETd 
values at distal range from Eclipse case, corresponding a high RBE value at same far range, 
and that what observed, and this corresponds to the positive relationship of each RBE and 
LETd as mentioned in 2.3.3 section. 
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6.2 Patient plan results 
6.2.1 Comparison of RBE 1.1. dose 
The dose distribution in both FLUKA(RBE1.1) and Eclipse (TPS(RBE1.1)) where RBE of 
1.1 utilized in Eclipse also, of Field-1, can be studied through Figures 33, 34 and 35 which 




Figure 33. Illustration a calculation of dose distributions of Field-1 in accordance with both 
FLUKA(RBE1.1) and Eclipse (TPS) with shows the dose difference of them on the right side, the 
PTV is delineated with a light blue circle in addition of the OARs which includes of brainstem a 
green color, temporal lobes, and hippocampus for both side of head patient purple and small light 





      Figure 34. DVH of Eclipse (TPS (RBE1.1)), dotted-line, and FLUKA(RBE1.1), solid-line, of 
Field-1 in order to compared doses for PTV and OARs. 
 
The figures demonstrate that the doses from both techniques are almost identical for the 
PTV region, and in the brainstem and temporal lobes-left side there is very little difference 
the doses. With a view to the dose temporal lobes-Right side calculated by the 
FLUKA(RBE1.1) technique are slightly increasing over of Eclipse (TPS) technique and 
apparently as shown in Figure 33-C from dose difference, the difference of dose in a 
hippocampus-Right appears of FLUKA(RBE1.1) technique uses, unlike the dose of in the 
hippocampus-Left calculated through the Eclipse (TPS) technique being close to FLUKA 
(RBE1.1) dose calculation value. In dose difference of Figure 33-C, the area between PTV 
region and temporal lobes-Right side appeared higher biological dose from FLUKA 
calculation than Eclipse. The scheme of maximum and mean dose displays the variation 





Figure 35. Scheme of maximum and mean dose for FLUKA(RBE1.1) and Eclipse (TPS) of 
Field-1 to the interested areas. 
 
 
Figure 36. Illustration a calculation of dose distributions of Field-2 in accordance with both 
FLUKA(RBE1.1) and Eclipse (TPS) with shows the dose difference of them on the right side, the 
PTV is delineated with a light blue circle in addition of the OARs which includes of brainstem a 
green color, temporal lobes, and hippocampus for both side of head patient purple and small light 




The dose difference of Field-2 by dose distribution as Figure 36-C indicates to high dose in 
the area between the PTV region and temporal lobes L side for the good of FLUKA(RBE1.1) 
than Eclipse (TPS) and especially on the side of Hippo L, for the opposite side for the same 
area dose difference becomes higher for the Eclipse (TPS) this time. 
Both Figure 37 of DVH and Figure 38 of Max/Mean dose for Field-2 show identical dose in 
the PTV region and also with a small difference for the brainstem dose and temporal lobes-
Right side in both techniques, but there was an increase of hippocampus-Right side dose 
from the Eclipse (TPS) calculation technique compared to the FLUKA(RBE1.1) dose. There 
is a biological dose undesirable between PTV regional and temporal lobes-Left side the 
Figure 36-C showed about 3 Gy(RBE) from FLUKA(RBE1.1) and including hippocampus-
Left side also . In accordance with analysing the data and figures, there is a great 
convergence between the two method calculations if the organ at interest not at the distal 
range of the field. 
 
 
Figure 37. DVH of Eclipse (TPS(RBE1.1)), dotted line, and FLUKA(RBE1.1), solid-line, of 





Figure 38. Scheme of maximum and mean dose for FLUKA(RBE1.1) and Eclipse TPS) of Field-
2 to the interested areas. 
 
Noticeable from Figure 39 the dose difference displays of the dose planned by both 
FLUKA(RBE1.1) and Eclipse (TPS). The PTV region, and both brainstem and temporal 
lobes of the head patient are almost completely identical with increasing a very slight 
difference of dose FLUKA(RBE1.1) technique calculate for the PTV region where take dose 
value below 55 Gy(RBE). This is confirmed by the scheme dose-volume histogram (DVH), 
Figure 39, where most of the OARs structures and PTV region are equal in dose except the 
hippocampus-Left side which shows a difference in the dose calculation of both techniques. 
At the same time, the hippocampus area displayed a FLUKA(RBE1.1) dose of approximately 
2-3 Gy higher than the Eclipse (TPS) dose. As well as, Figure 39-C illustrates a high dose in 
the area between the PTV region and temporal lobes for both sides for the benefit of FLUKA 
calculation. Figure 41 below, illustrates the Max/Mean dose of the PTV region and the 
OARs, and demonstrate the close match of doses calculated using both FLUKA(RBE1.1) and 
Eclipse (TPS) technique. The scheme from Max/Mean dose gives a good indication of the 




Figure 39. Illustration a calculation of dose distributions of All-Fields in accordance with both 
FLUKA(RBE1.1) and Eclipse (TPS) with shows the dose difference of them on the right side, the 
PTV is delineated with a light blue circle in addition of the OARs which includes of brainstem a 
green color, temporal lobes, and hippocampus for both side of head patient purple and small light 
blue ring color respectively. 
 
 
Figure 40. DVH of Eclipse (TPS(RBE1.1)), dotted-line, and FLUKA(RBE1.1), solid-line, of All-





Figure 41. scheme of maximum and mean dose for FLUKA(RBE1.1) and Eclipse (TPS) of All-
Fields to the interested areas. 
 
Comparison of Physical dose calculated from FLUKA and Eclipse 
Micro-Calcualtion script 
Through operates in the same approach of water phantom physical dose analysis, Figure 43 
displays the physical dose to the FLUKA recalculation of the patient treatment plan and to the 
Eclipse Micro-Calculation script at 17% of normalization plan mode from Eclipse (TPS) and 
this shows for the right side in Figure 42, where the graph demonstrates the Eclipse Micro-
Calculation biological dose pre and post normalization plan, having regard to a converging 






Figure 42. Dose-profile (DP) of Eclipse (TPS), light-blue line, and Eclipse Micro-Calculation, red 




Figure 43. Physical dose distribution of FLUKA and Eclipse Micro-Calculation script for Field-1, 




Through the color wash bar analysis in Figure 43, especially to the PTV position, it had been 
determined a PTV physical dose distribution of 49 Gy at treatment plan by Eclipse, and the 
FLUKA recalculation gave good and near results of the prescription dose value. However, the 
Eclipse Micro-Calculation script has exceeded ≈ 10Gy of dose value before normalized. Since 
there was a slight difference in the dose value for both methods in the case of water phantom 
despite the utilize of a homogeneous medium, it is expected that the dose difference will 
become greater when the field penetration in a non-homogeneous medium. 
6.2.1 LET of Patient Plan 
For the case of Field-1, through Figure 44 of LETd distribution and by Figure 45 of LETd 
VH, the LETd value increases as the penetration at the distal beam for both technique and it 
has been observed a difference in LETd computation through FLUKA and Eclipse methods, 
the latter shows higher LETd values compared to FLUKA on most OARs, except the 
temporal lobes R organ where at V50% the Eclipse LETd value less than 6 keV/µm, whereas at 
the same volume the FLUKA LETd less than 10 keV/µm and brainstem have some different 
with various LETd value. By taking a peek, in Figure 44, the color wash bar of the 
FLUKA(LETd) and Eclipse (LETd) distribution emphasizes the outcomes at the distal range 
have a high LETd value corresponding with low dose distribution (see section 6.2.1). 
In addition, the difference between both techniques become bigger of LETd in the organ's 
place located far from the beam penetration path, this appears for the place of the organs 
located at far of the field side, like temporal lobes R side and hippocampus R side status.  
 However, the PTV region different among the two methods circa/less 1 keV/µm and they 





Figure 44. Illustration the LETd of Field-1 for PTV and OARs. 
 
 
Figure 45. LETd volume histogram of Eclipse (TPS), dotted-line, and FLUKA(RBE1.1), solid-
line, of Field-1 in order to compared LETd for PTV and OARs. 
 
By inspecting Figures 46 and 47 both, we see a difference in LETd distribution and LET-
VH, Figure 46 presents between the two methods with the LETd value for the good of 
Eclipse than FLUKA for the PTV region and some of the OARs, except the temporal lobes L 
side and Brainstem, tend high to the good of FLUKA. The left side organs this time have a 
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high difference especially for temporal lobes L side organ, at V30% the LETd value takes less 
than 4 keV/µm value approximately for Eclipse, in contrast, LETd takes less than 13 keV/µm 
value for FLUKA technique. The PTV region had a similar shift of LETd value for Field-1 
case. 
 FLUKA and Eclipse calculation with outcomes similar to the Filed-1 case again with 
increases LETd value at distal range of fields as Figure 46 shows, specifically for the organs 
located at a far distance of beams. 
 
 





Figure 47. LETd VH of Eclipse (TPS), dotted-line, and FLUKA(RBE1.1), solid-line, of 
Field-2 in order to compared doses for PTV and OAR. 
 
It found the effect of the two fields combined made LETd values of Eclipse and FLUKA less 
than LETd of the singular fields status with keep of LETd by Eclipse technique higher than 
FLUKA, and maintain LETd value of Brainstem organ at the same value roughly, as Figure 
49 from LETd VH. 
 From the LETd VH, as seen in Figure 49, it is seen that the dissimilarity of PTV LETd 
values calculated by FLUKA and Eclipse preserved ≈ 1 keV/µm with reduces in a total LETd 
value from the case of the single fields, LETd becomes 3 keV/µm and under 4 keV/µm for 
FLUKA and Eclipse at attending sequence. The LETd distribution through color wash in 
Figure 48 shows the variation of LETd for the PTV region and OARs from both techniques 
in general and with eye up of on the areas upper of the PTV region of both technique in 
Figure 48, it found were also exposed to high LETd value, where FLUKA gave higher 
outcomes compared to Eclipse. 
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According to the biological/ or physical dose distribution from FLUKA and Eclipse, they 
found at each low dose region corresponding to a high LETd value as visualize by Figures 46 
and 44, and the opposite is true. 
 
 
Figure 48. Illustration the LETd of All-Fields for PTV and OARs. 
 
 
Figure 49. LETd VH of Eclipse (TPS), dotted-line, and FLUKA(RBE1.1), solid-line, of All-




6.2.2 RBE McNamara model 
 
 
Figure 50. RBE of MCN model by FLUKA and Eclipse Micro-Calculation script for patient 
treatment plan, first, middle and last column represents the Field-1, Filed-2, and All Fields 
respectively, the first and second row presents from FLUKA and Eclipse, slice N.50. 
 
 
Figure 51. RBE of MCN model by FLUKA and Eclipse Micro-Calculation script for patient 
treatment plan, first, middle and last column represents the Field-1, Filed-2, and All Fields 





Figure 52. RBE of MCN model by FLUKA and Eclipse Micro-Calculation script for patient 
treatment plan, first, middle and last column represents the Field-1, Filed-2, and All Fields 
respectively, the first and second row presents from FLUKA and Eclipse, slice N.55. 
 
It has been plotted different slices for each of Eclipse Micro-Calculation and FLUKA in order 
to attempt to show the highest RBE-MCN value for organs at interest in this study work and 
the extent to which the RBE-MCN correlate with the LETd outcomes generally, where the 
alpha/beta utilized in Eclipse as aforementioned in 5.8 section and in FLUKA 3 Gy. 
Regarding to the Field-1 status, the beam inlet at temporal lobes L side region had RBE value 
at under 1.3 to FLUKA and at 1.125 for Eclipse with increasing of RBE value whenever the 
Field penetrates forward, and this show by Figure 50, the Figure 51 and 52 demonstrates 
RBE value of temporal lobes R side organ which take high value at 2.2 for FLUKA case and 
about less 2.1 to Eclipse, this RBE value occupied most of the organ's volume from FLUKA 
and less half organ's volume for Eclipse and this corresponded through LETd VH in Figure 
45. Overall, the RBE value of FLUKA high than Eclipse status for organs in case Field-1. 
Regarding the Field-2, and through temporal lobes R side this time, the RBE value take below 
1.3 for FLUKA, and RBE starting at 1.125 to the Eclipse, look in Figure 50 and 51, in 
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addition, the RBE of temporal lobes L side takes the highest value by FLUKA of 2.2 and less 
this value for Eclipse, this is well shown in Figure 50 especially, the FLUKA has on a top value 
of RBE than Eclipse at the studied organs as in the Field-1 case also. 
And back to both fields, Figure 50 demonstrates the RBE from Eclipse of the Brainstem organ 
has close value to the RBE from FLUKA with taking into consideration the high value for 
FLUKA always, the hippocampus L of FLUKA takes around 1.4 of RBE with slightly more 
value for Eclipse, the inner sides of the temporal lobes L and temporal lobes R have high RBE 
up to approx. 1.5 regarding to the Eclipse Micro-Calculation and it increases for FLUKA 
status. 
By analysing the shapes of FLUKA for both fields, Figure 50,51, and 52, it notes areas up and 
down between the temporal lobes L and temporal lobes R have been exposed to high RBE 





Proceeding from the water phantom status the biological dose distribution calculated by the 
Eclipse (TPS(RBE1.1)) method gave consequence exceed the dose prescription dose 2 Gy in 
the PTV region, the maximum dose, Dmax, above 2 Gy, as Figure 25-I and scheme of DVH 
in Figure 26 shows. The water LETd results demonstrated a small constant difference at all 
the volume of the PTV region either for singular or both fields from FLUKA and Eclipse 
Micro-Calculation, the latter had high LETd at all Fields cases, but LETd did not exceed 5 
keV/µm for the PTV region, but was over this value for distal end of singular field from both 
methods. The RBE-MCN water phantom result concurred with LETd outcome as a linear 
RBE-LETd relationships for both fields of Eclipse Micro-Calculation and FLUKA, where the 
RBE-MCN of PTV region according to the Eclipse Micro-Calculation result came under 1.1 
at singular fields as Figure 31 and 32 shows and above of 1.1 for FLUKA calculation although 
the Eclipse had upper of LETd valued than FLUKA, at the remote end of Field-1 and Field-
2, the RBE-MCN value increased atop 1.1 as LETd raised for both methods. 
Regard to the patient's condition shows great conformity of biological dose from both 
techniques. The outcomes indicated a suitable match in calculating the dose with the 
exception of some areas where there was some difference in the biological dose calculated for 
both methods on hippocampus L and hippocampus R side for Field-1and Field-2 status 
respectively as mentioned in the results chapter. In the case of singular fields, it was found 
that the dose in the PTV region is an almost match by FLUKA(RBE1.1) and Eclipse 
(TPS(RBE1.1)) and the PTV region attained the dose for both methods under 40 Gy(RBE) 
as Figures 34 and 37 displayed. The OARs received doses from Field -1 and Field-2 less than 
30 Gy(RBE), except the Brainstem and hippocampus R side exposed  40 Gy(RBE) and 
below 35 Gy(RBE) respectively. 
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Upon returning to the sum of the total effect of the two fields together, ALL-Field state, the 
PTV region attained a slightly more prescription dose ≈ 55 Gy(RBE) and also Brainstem 
gained 54 Gy(RBE) approximately due to a near Brainstem location from the PTV region 
and the rest of OARs received under 50 Gy(RBE) overall.  
As for the OARs areas, when one of the areas to be calculated dose distribution is close to the 
oriented field side on it, we find there is a near match with a slight difference in the dose 
calculation for both methods and a notable difference in the dose calculation for both 
FLUKA(RBE1.1) and Eclipse (TPS(RBE1.1)) technique in the moment the target area is far 
from the oriented field.  This applies to all tissues except for hippocampus L, we found a 
difference in the calculation of the dose of both Fields as Figure 40 shows. 
The presence of heterogeneity in the tissues along the pathway of filed track thus induces 
contradiction of calculation of the dose in both FLUKA(RBE1.1) and Eclipse 
(TPS(RBE1.1)) used Pencil-beam scanning technique due to in the dosimetric calculation in 
the Pencil-beam algorithm take into account the dose kernel inside the homogeneous 
tissue/medium to calculate the absorbed dose with taking consideration of the correction of 
inhomogeneity tissue in term of longitudinal direction in the core beam axis with ignoring 
the lateral scatter(Balagamwala et al., 2012).  It can be said that the method of recalculating 
the dose by FLUKA(RBE1.1) is almost identical with Eclipse (TPS(RBE1.1)) calculation for 
this case of head-patient treatment kind of PTV. 
By looking at the LETd consequences, the small constant difference of LETd in water 
phantom status, converted to the random difference at PTV and OARS, the reason is due to 
the nature of brain inhomogeneous medium, with LETd values remaining of Eclipse higher 
than FLUKA with the exception of some of the OARs as mentioned in the result section. 
Generally, the LETd values for organs located at a proximal range of singular fields received 
under 6 keV/µm and for distal range exceeded 7 keV/µm and reach in some of the OARs up 
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to 16 keV/µm, as estimated by FLUKA. MC code are in general more precise in low-dose 
regions and this could be the reason for the large difference for some OARs. 
Simultaneously, RBE values increase as LETd value increases along beam penetration 
forward, and FLUKA calculation demonstrated RBE values higher from Eclipse Micro-
Calculation on each single and both fields excluding hippocampus L side where RBE-MCN 
through Eclipse Micro-Calculation have high RBE value than FLUKA in the case of Both 
fields.  
Through FLUKA calculations, the maximum of RBE reached to the 2.2 in some of the 





The simulation FLUKA MC and Eclipse of water phantom shows overall relatively good 
agreement, similarly, in terms to patient plan, the upshots of biological dose distribution 
through FLUKA MC and Eclipse (TPS(RBE1.1)) exhibits agreement on the outcomes where 
the difference between them was most pronounced at organs located at a far distance from 
the singular field and a good match for both fields case except hippocampus L side. 
According to both methods and through color wash distribution of LETd and RBE, some 
areas/organs outrange of the studied organs were exposed to the high LET and RBE value as 
Figures 48 and 52 illustrated of both fields. 
The Micro-calculation script which was utilized by Eclipse software in order to LETd and 
RBE-MCN calculations gave outputs closely to the FLUKA MC in some cases and far from 
others, the RBE value not constant at 1.1 and increased at distal range of field. 
Accordingly, the trend in the RBE values are similar to previously published results. This 
thesis shows that both FLUKA and Eclipse can be used to obtain LETd, but one should be 
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